Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C36H50O6 |
| Molecular Weight | 578.7786 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 2 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12CC[C@](O)(C(=O)COC(=O)\C=C(/C)CC\C=C(/C)CCC=C(C)C)[C@@]1(C)C[C@H](O)[C@@]3([H])[C@@]2([H])CCC4=CC(=O)C=C[C@]34C
InChI
InChIKey=SBQAKZYUNWNIRL-WIPKXTQKSA-N
InChI=1S/C36H50O6/c1-23(2)9-7-10-24(3)11-8-12-25(4)19-32(40)42-22-31(39)36(41)18-16-29-28-14-13-26-20-27(37)15-17-34(26,5)33(28)30(38)21-35(29,36)6/h9,11,15,17,19-20,28-30,33,38,41H,7-8,10,12-14,16,18,21-22H2,1-6H3/b24-11+,25-19+/t28-,29-,30-,33+,34-,35-,36-/m0/s1
| Molecular Formula | C36H50O6 |
| Molecular Weight | 578.7786 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 7 / 7 |
| E/Z Centers | 2 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: http://www.thepharmaletter.com/article/prednisolone-farnesylate-launch-in-japan; http://adisinsight.springer.com/drugs/800002180
Curator's Comment: http://www.thepharmaletter.com/article/prednisolone-farnesylate-launch-in-japan; http://adisinsight.springer.com/drugs/800002180
Prednisolone farnesylate, a synthetic glucocorticoid, is a terpene-modified compound of prednisolone with an antiinflammatory and antirheumatic action. Glucocorticoid receptor agonists. Farnerate Gel (trade name from Dainippon Pharmaceuticals) and Farnezone Gel (Taiho Pharmaceuticalshave) were launched in Japan in 1998 as topical rheumatoid arthritis (RA) product to treat symptoms associated with RA such as finger, hand and elbow swelling and pain.
CNS Activity
Curator's Comment: In the histological examinations, a decrease in the weight of the thymus and adrenal glands, atrophy of zona fasciculata of the adrenal glands, hypertrophy of zona glomeruli, swelling of cortical cells of zona faciculate and atrophy of the thymus were observed in the PNF gel administered percutaneously at doses 0.8 mg/kg/day in the Beagle dogs.
Originator
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| [A 52-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 8 weeks]. | 1992 Nov |
|
| [A 13-week dermal toxicity study of prednisolone farnesylate (PNF) gel in rats with a recovery period of 5 weeks]. | 1992 Nov |
|
| [Effects of prednisolone farnesylate (PNF) gel on skin and ocular mucosa]. | 1992 Nov |
|
| [Mutagenicity studies of prednisolone farnesylate (PNF)]. | 1992 Nov |
|
| [Reproductive and developmental toxicity study of prednisolone farnesylate (PNF)--teratogenicity study in rabbits by subcutaneous administration]. | 1992 Nov |
|
| [Reproductive and developmental toxicity study of prednisolone farnesylate (PNF)--study by subcutaneous administration of PNF prior to and in the early stages of pregnancy in rats]. | 1992 Nov |
|
| [A 52-week percutaneous toxicity study of prednisolone farnesylate (PNF) gel in beagle dogs with a recovery period of 8 weeks]. | 1992 Nov |
|
| [A 13-week percutaneous toxicity study of prednisolone farnesylate (PNF) gel in beagle dogs with a recovery period of 5 weeks]. | 1992 Nov |
|
| Diffusion and metabolism of prednisolone farnesylate in viable skin of the hairless mouse. | 1994 Mar |
|
| Treatment of the chronic inflammation in peripheral target tissue improves the crushed nerve recovery in the rat: histopathological assessment of the nerve recovery. | 2002 Oct 15 |
Sample Use Guides
Gel 14 mg/g (1.4%) is applied to treat symptoms of rheumatoid arthritis such as swelling and pain in the fingers, hands and elbows
Route of Administration:
Topical
Prednisolone farnesylate (PNF) was tested for mutagenicity by Ames test using Salmonella typhimurium (TA100, TA1535, TA98, TA1537) and Escherichia coli (WP2 uvrA), for clastogenic activity in vitro by the chromosomal aberration test in a Chinese hamster fibroblast cell line (CHL). In Ames test, PNF with and without metabolic activation showed no mutagenicity in any strains at any dose levels 312-5,000 micrograms/plate. n the chromosomal aberration test, PNF with metabolic activation produced a slight increase in the incidence of structural chromosomal aberrations in CHL cells at 1,500 micrograms/ml.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:10:18 GMT 2023
by
admin
on
Fri Dec 15 18:10:18 GMT 2023
|
| Record UNII |
359F2816ER
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
5282229
Created by
admin on Fri Dec 15 18:10:18 GMT 2023 , Edited by admin on Fri Dec 15 18:10:18 GMT 2023
|
PRIMARY | |||
|
C080069
Created by
admin on Fri Dec 15 18:10:18 GMT 2023 , Edited by admin on Fri Dec 15 18:10:18 GMT 2023
|
PRIMARY | |||
|
2248
Created by
admin on Fri Dec 15 18:10:18 GMT 2023 , Edited by admin on Fri Dec 15 18:10:18 GMT 2023
|
PRIMARY | |||
|
SUB22670
Created by
admin on Fri Dec 15 18:10:18 GMT 2023 , Edited by admin on Fri Dec 15 18:10:18 GMT 2023
|
PRIMARY | |||
|
359F2816ER
Created by
admin on Fri Dec 15 18:10:18 GMT 2023 , Edited by admin on Fri Dec 15 18:10:18 GMT 2023
|
PRIMARY | |||
|
DTXSID0057625
Created by
admin on Fri Dec 15 18:10:18 GMT 2023 , Edited by admin on Fri Dec 15 18:10:18 GMT 2023
|
PRIMARY | |||
|
118244-44-3
Created by
admin on Fri Dec 15 18:10:18 GMT 2023 , Edited by admin on Fri Dec 15 18:10:18 GMT 2023
|
PRIMARY | |||
|
100000091338
Created by
admin on Fri Dec 15 18:10:18 GMT 2023 , Edited by admin on Fri Dec 15 18:10:18 GMT 2023
|
PRIMARY |